RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) no errors detected.

Application Serial Number:	10/541,771
Source:	PUTIO
Date Processed by STIC:	7/19/05

ENTERED



PCT

```
DATE: 07/19/2005
                     RAW SEQUENCE LISTING
                     PATENT APPLICATION: US/10/541,771 TIME: 15:25:13
                     Input Set : A:\PTO.YF.txt
                     Output Set: N:\CRF4\07192005\J541771.raw
      7 <110> APPLICANT: The Wistar Institute
              Gerhard , Walter
              Otvos, Laszlo
     9
     11 <120> TITLE OF INVENTION: COMPOSITION AND METHOD FOR PREVENTING OR TREATING A VIRUS
             INFECTION
     14 <130> FILE REFERENCE: WSTR-0017C
C--> 16 <140> CURRENT APPLICATION NUMBER: US/10/541,771
C--> 16 <141> CURRENT FILING DATE: 2005-07-08
     16 <150> PRIOR APPLICATION NUMBER: US 60/441,374
     17 <151> PRIOR FILING DATE: 2003-01-16
     19 <160> NUMBER OF SEQ ID NOS: 10
     21 <170> SOFTWARE: PatentIn version 3.1
     24 <210> SEQ ID NO: 1
     25 <211> LENGTH: 5
     26 <212> TYPE: PRT
     27 <213> ORGANISM: Artificial Sequence
     29 <220> FEATURE:
     30 <223> OTHER INFORMATION: Synthetic multiple antigenic agent
     32 <220> FEATURE:
     34 <221> NAME/KEY: MISC FEATURE
     35 <222> LOCATION: (1)..(1)
     36 <223> OTHER INFORMATION: N-terminal amino group has attached R1 which is 0 to 2 amino
acid
              residues, wherein said amino acid residue may be a Gly or Cys, or a nucleic
     37
     38
             acid sequence.
     40 <220> FEATURE:
     41 <221> NAME/KEY: MISC FEATURE
     42 <222> LOCATION: (1)..(1)
     43 <223> OTHER INFORMATION: Side chain amino group has attached R2 which is a B cell
determinant, a T
             cell determinant, or a targeting molecule.
     46 <220> FEATURE:
     47 <221> NAME/KEY: MISC_FEATURE
     48 <222> LOCATION: (3)..(3)
     49 <223> OTHER INFORMATION: Side chain amino group has attached R3 which is a B cell
determinant, a T
             cell determinant, or a targeting molecule.
     52 <220> FEATURE:
     53 <221> NAME/KEY: MISC FEATURE
     54 <222> LOCATION: (5)..(5)
     55 <223> OTHER INFORMATION: "Xaa" represents 0 to 1 amino acid residue of Lys-R4, wherein
R4
             is a B cell determinant, a T cell determinant, or a targeting molecule.
```

58 <220> FEATURE:

```
59 <221> NAME/KEY: MISC_FEATURE
60 <222> LOCATION: (5)..(5)
62 <223> OTHER INFORMATION: C-terminus has attached R5 group which is an amino acid, peptide, or
```

```
RAW SEQUENCE LISTING
                                                             DATE: 07/19/2005
                     PATENT APPLICATION: US/10/541,771
                                                            TIME: 15:25:13
                     Input Set : A:\PTO.YF.txt
                     Output Set: N:\CRF4\07192005\J541771.raw
1
     63
              nucleic acid sequence.
     65 <400> SEQUENCE: 1
W--> 66 Lys Gly Lys Gly Xaa
     67 1
     70 <210> SEQ ID NO: 2
     71 <211> LENGTH: 14
     72 <212> TYPE: PRT
     73 <213> ORGANISM: Artificial Sequence
     75 <220> FEATURE:
     76 <223> OTHER INFORMATION: Synthetic multiple antigenic agent
     78 <220> FEATURE:
     79 <221> NAME/KEY: MISC FEATURE
     80 <222> LOCATION: (1)..(1)
     81 <223> OTHER INFORMATION: Mannosylated residue
     83 <220> FEATURE:
     84 <221> NAME/KEY: MISC FEATURE
     85 <222> LOCATION: (2)..(2)
     86 <223> OTHER INFORMATION: Mannosylated serine residue attached to side chain amino
group
     88 <220> FEATURE:
     89 <221> NAME/KEY: MISC FEATURE
     90 <222> LOCATION: (4)..(4)
     91 <223> OTHER INFORMATION: Mannosylated serine residue attached to side chain amino
     93 <220> FEATURE:
     94 <221> NAME/KEY: MISC FEATURE
     95 <222> LOCATION: (6)..(6)
    96 <223> OTHER INFORMATION: Mannosylated serine residue attached to side chain amino
group
    98 <220> FEATURE:
    99 <221> NAME/KEY: MISC FEATURE
    100 <222> LOCATION: (8)..(8)
    101 <223> OTHER INFORMATION: S2 peptide attached to side chain amino group
    103 <220> FEATURE:
    104 <221> NAME/KEY: MISC FEATURE
    105 <222> LOCATION: (10)..(10)
    106 <223> OTHER INFORMATION: S1 peptide attached to side chain amino group
    108 <220> FEATURE:
    109 <221> NAME/KEY: MISC FEATURE
    110 <222> LOCATION: (12)..(12)
    111 <223> OTHER INFORMATION: M2e peptide attached to side chain amino group
    113 <400> SEQUENCE: 2
    114 Ser Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala
    115 1
    118 <210> SEQ ID NO: 3
    119 <211> LENGTH: 13
    120 <212> TYPE: PRT
    122 <213> ORGANISM: Artificial Sequence
    124 <220> FEATURE:
    125 <223> OTHER INFORMATION: Synthetic multiple antigenic agent
    127 <220> FEATURE:
```

128 <221> NAME/KEY: MISC FEATURE

RAW SEQUENCE LISTING DATE: 07/19/2005 PATENT APPLICATION: US/10/541,771 TIME: 15:25:13

Input Set : A:\PTO.YF.txt

Output Set: N:\CRF4\07192005\J541771.raw

- 129 <222> LOCATION: (3)..(3)
- 130 <223> OTHER INFORMATION: Serine attached to side chain amino group
 - 132 <220> FEATURE:
 - 133 <221> NAME/KEY: MISC FEATURE
 - 134 <222> LOCATION: (5)..(5)
 - 135 <223> OTHER INFORMATION: Serine attached to side chain amino group
 - 137 <220> FEATURE:
 - 138 <221> NAME/KEY: MISC_FEATURE
 - 139 <222> LOCATION: (7)..(7)
 - 140 <223> OTHER INFORMATION: S2 peptide attached to side chain amino group
 - 142 <220> FEATURE:
 - 143 <221> NAME/KEY: MISC FEATURE
 - 144 <222> LOCATION: (9)..(9)
 - 145 <223> OTHER INFORMATION: S1 peptide attached to side chain amino group
 - 147 <220> FEATURE:
 - 148 <221> NAME/KEY: MISC FEATURE
 - 149 <222> LOCATION: (11)..(11)
 - 150 <223> OTHER INFORMATION: M2e peptide attached to side chain amino group
 - 152 <400> SEQUENCE: 3
 - 153 Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala
 - 154 1 5 10
 - 157 <210> SEQ ID NO: 4
 - 158 <211> LENGTH: 12
 - 159 <212> TYPE: PRT
 - 160 <213> ORGANISM: Artificial Sequence
 - 162 <220> FEATURE:
 - 163 <223> OTHER INFORMATION: Synthetic multiple antigenic agent
 - 165 <220> FEATURE:
 - 166 <221> NAME/KEY: MISC FEATURE
 - 167 <222> LOCATION: (2)..(2)
 - 168 <223> OTHER INFORMATION: Serine residue attached to side chain
 - 170 <220> FEATURE:
 - 171 <221> NAME/KEY: MISC_FEATURE
 - 172 <222> LOCATION: (4)..(4)
 - 173 <223> OTHER INFORMATION: S2 peptide attached to side chain amino group
 - 175 <220> FEATURE:
 - 176 <221> NAME/KEY: MISC_FEATURE
 - 177 <222> LOCATION: (6)..(6)
 - 178 <223> OTHER INFORMATION: S1 peptide attached to side chain amino group
 - 181 <220> FEATURE:
 - 183 <221> NAME/KEY: MISC FEATURE
 - 184 <222> LOCATION: (8)..(8)
 - 185 <223> OTHER INFORMATION: M2e peptide attached to side chain amino group
 - 187 <220> FEATURE:
 - 188 <221> NAME/KEY: MISC FEATURE
 - 189 <222> LOCATION: (10)..(10)
 - 190 <223> OTHER INFORMATION: M2e peptide attached to side chain amino group
 - 192 <400> SEQUENCE: 4
 - 193 Ser Cys Gly Lys Gly Lys Gly Lys Gly Ala

DATE: 07/19/2005

TIME: 15:25:13 PATENT APPLICATION: US/10/541,771 Input Set : A:\PTO.YF.txt Output Set: N:\CRF4\07192005\J541771.raw 194 1 10 197 <210> SEQ ID NO: 5 198 <211> LENGTH: 11 199 <212> TYPE: PRT 200 <213> ORGANISM: Artificial Sequence 202 <220> FEATURE: 203 <223> OTHER INFORMATION: Synthetic multiple antigenic agent 205 <220> FEATURE: 206 <221> NAME/KEY: MISC FEATURE 207 <222> LOCATION: (1)..(1) 208 <223> OTHER INFORMATION: Dimer created by disulfide linkage 210 <220> FEATURE: 211 <221> NAME/KEY: MISC FEATURE 212 <222> LOCATION: (3)..(3) 213 <223> OTHER INFORMATION: S2 peptide attached to side chain amino group 215 <220> FEATURE: 216 <221> NAME/KEY: MISC FEATURE 217 <222> LOCATION: (5)..(5) 218 <223> OTHER INFORMATION: S1 peptide attached to side chain amino group 220 <220> FEATURE: 221 <221> NAME/KEY: MISC FEATURE 222 <222> LOCATION: (7)..(7) 223 <223 > OTHER INFORMATION: M2e peptide attached to side chain amino group 225 <220> FEATURE: 226 <221> NAME/KEY: MISC_FEATURE 227 <222> LOCATION: (9)..(9) 228 <223> OTHER INFORMATION: M2e peptide attached to side chain amino group 230 <400> SEQUENCE: 5 231 Cys Gly Lys Gly Lys Gly Lys Gly Ala 232 1 10 235 <210> SEQ ID NO: 6 236 <211> LENGTH: 8 237 <212> TYPE: PRT 238 <213> ORGANISM: Artificial Sequence 240 <220> FEATURE: 241 <223> OTHER INFORMATION: Synthetic multiple antigenic agent 243 <400> SEQUENCE: 6 244 Cys Gly Lys Gly Lys Ala 245 1 248 <210> SEQ ID NO: 7 249 <211> LENGTH: 8 250 <212> TYPE: PRT 251 <213> ORGANISM: Artificial Sequence 253 <220> FEATURE:

254 <223> OTHER INFORMATION: Synthetic multiple antigenic agent

259 <223> OTHER INFORMATION: M2e petide attached to side chain amino group

RAW SEQUENCE LISTING

257 <221> NAME/KEY: MISC_FEATURE 258 <222> LOCATION: (3)..(3)

256 <220> FEATURE:

RAW SEQUENCE LISTINGPATENT APPLICATION: **US/10/541,771**DATE: 07/19/2005 TIME: 15:25:13

Input Set : A:\PTO.YF.txt

```
Output Set: N:\CRF4\07192005\J541771.raw
261 <220> FEATURE:
262 <221> NAME/KEY: MISC FEATURE
263 <222> LOCATION: (5)..(5)
264 <223> OTHER INFORMATION: M2e petide attached to side chain amino group
266 <400> SEQUENCE: 7
267 Cys Gly Lys Gly Lys Gly Lys Ala
271 <210> SEQ ID NO: 8
.272 <211> LENGTH: 11
273 <212> TYPE: PRT
274 <213> ORGANISM: Artificial Sequence
276 <220> FEATURE:
277 <223> OTHER INFORMATION: Synthetic S1 peptide
279 <400> SEQUENCE: 8
280 Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu
281 1
                    5
284 <210> SEQ ID NO: 9
285 <211> LENGTH: 13
286 <212> TYPE: PRT
287 <213> ORGANISM: Artificial Sequence
289 <220> FEATURE:
290 <223> OTHER INFORMATION: Synthetic S2 peptide
292 <400> SEQUENCE: 9
293 His Asn Thr Asn Gly Val Thr Ala Ala Ser Ser His Glu
297 <210> SEQ ID NO: 10
298 <211> LENGTH: 24
299 <212> TYPE: PRT
300 <213> ORGANISM: Artificial Sequence
303 <220> FEATURE:
304 <223> OTHER INFORMATION: Synthetic M2e peptide
306 <400> SEQUENCE: 10
307 Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly Cys
                    5
                                         10
310 Arg Ser Asn Asp Ser Ser Asp Pro
```

311

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 07/19/2005 PATENT APPLICATION: US/10/541,771 TIME: 15:25:14

Input Set : A:\PTO.YF.txt

Output Set: N:\CRF4\07192005\J541771.raw

Please Note:

Uşe of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 5

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 37,43,49

VERIFICATION SUMMARY

DATE: 07/19/2005 TIME: 15:25:14

PATENT APPLICATION: US/10/541,771

Input Set : A:\PTO.YF.txt

Output Set: N:\CRF4\07192005\J541771.raw

L:16 M:270 C: Current Application Number differs, Replaced Current Application No L:16 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:66 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0